გთხოვთ გაეცნოთ

Dear Tamar,

Following the Memorandum of Understanding signed with Johnson & Johnson (Janssen), I am pleased to inform you that today 22nd March 2021 marks the opening of Purchase Opportunity “Window 1” for the Johnson & Johnson (Janssen) Ad26COV2.S vaccine candidate. This “Window 1” will be open until Tuesday 6th April 2021. If you wish to opt-out during “Window 1” please submit a Non-Participation Notice to covax@gavi.org by 23:59 CET on 6th April 2021.  

Please find attached an information pack including technical characteristics of the vaccine, clinical and regulatory strategies, and indicative deal terms with COVAX, as well as an Annex with all publications and relevant press releases to guide your decision making.  

First opt-out Window for vaccine candidates 

Window 1 occurs before the Facility signs an Advance Purchase Agreement (APA) with the relevant manufacturer. If you wish to opt-out of purchasing doses of this vaccine candidate, please notify the COVAX Facility by completing a Non-Participation Notice as set out in Schedule 2 of the Commitment Agreement, attached in Word for ease of completion. If you decide to opt-out, you will not be issued any purchase options at the Purchase Option window (“Window 2”) to procure doses of Johnson & Johnson (Janssen) Ad26COV2.S vaccine candidate. The decision to opt-out at Window 1 cannot be changed at a later stage. 

If you do not wish to opt-out and you wish to participate in this deal, no further action is required. In this case, you will receive your pro-rata share of doses - total allocation of doses of a specific vaccine - from this manufacturer in line with the WHO allocation model [as a purchase option at Window 2]. 

Next Step: Second opt-out Window 

Following the signing of the Advance Purchase Agreement with Johnson & Johnson (Janssen), we will open the Window 2 for Johnson & Johnson (Janssen). The Window 2 purchase option will be offered to Participants that have not opted-out, and chose to participate in this deal, at Window 1.  

At the opening of Window 2 we will share the following information: 

·         Updated information pack 

·         Price per dose of the Johnson & Johnson (Janssen) candidate 

·         Your country’s pro-rata share of doses of the Johnson & Johnson (Janssen) candidate  

·         Total Purchase value for the Johnson & Johnson (Janssen) candidate based on your pro-rata share 

·         Upfront payment required by the relevant manufacturer. Note that pursuant to Clause 4.1(e) of the Commitment Agreement and paragraph 10 of the Terms and Conditions, the Participant will not be entitled to its Prepaid Doses if it delivers a Non-Exercise Notice to Gavi and “opts out at Window 2”. In this situation, the Facility will not refund the Participant’s share of the upfront payment that was made to the manufacturer. 

Novavax

The Purchase Opportunity “Window 1” for the Novavax NVX-CoV2373 vaccine candidate closed on 12th March 2021. Hereby, we would like to confirm that Georgia did not submit a non-participation notice and can expect to receive its pro-rata share of doses from NOVAVAX in line with the WHO allocation model. Following the signing of the Advance Purchase Agreement with NOVAVAX, the Facility will open the Purchase Option “Window 2” for that manufacturer. 

For further information please refer to the Options Explainer. With the progression of negotiations with other candidates in the COVAX Facility portfolio, COVAX will inform you about windows for other vaccine candidates.   

Please let me know if you have any questions.  

Best wishes

Rosie

Rosie Grieves

Senior Manager Country Engagement 

Mobile: +44 7849 574189

Web: gavi.org

NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners.

If this email was sent to you in error, please notify the send